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Available online 13 May 2016Genomic landscapes of 92 adult and 111 pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL)
were investigated using next-generation sequencing and copy number alteration analysis. Recurrent genemuta-
tions and fusions were tested in an additional 87 adult and 93 pediatric patients. Among the 29 newly identiﬁed
in-frame gene fusions, those involving MEF2D and ZNF384 were clinically relevant and were demonstrated to
perturb B-cell differentiation, with EP300-ZNF384 inducing leukemia in mice. Eight gene expression subgroups
associated with characteristic genetic abnormalities were identiﬁed, including leukemia with MEF2D and
ZNF384 fusions in two distinct clusters. In subgroup G4 which was characterized by ERG deletion, DUX4-IGH fu-
sion was detected in most cases. This comprehensive dataset allowed us to compare the features of molecular
pathogenesis between adult and pediatric B-ALL and to identify signatures possibly related to the inferior out-
come of adults to that of children. We found that, besides the known discrepancies in frequencies of prognostic
markers, adult patients had more cooperative mutations and greater enrichment for alterations of epigenetic
modiﬁers and genes linked to B-cell development, suggesting difference in the target cells of transformation be-
tween adult and pediatric patients and may explain in part the disparity in their responses to treatment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Adult B-ALL
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ZNF384 fusionsequally to this work.
. This is an open access article under1. Introduction
Acute lymphoblastic leukemia (ALL) results from the clonal prolifer-
ation of lymphoid stem or progenitor cells, with more than 80% being
originated from B-cell progenitors (B-ALL) (Pui, 2010). Recurrentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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key roles in ALL pathogenesis, frequently by targeting vital molecular
components of hematopoietic differentiation, cell cycling, tumor sup-
pression and stem cell self-renewal (Roberts et al., 2012). The identiﬁca-
tion of these abnormalities not only reveals underlying molecular
pathology, but also provides important therapeutic targets, as exempli-
ﬁed by the improved outcome achievedwith ABL tyrosine kinase inhib-
itors in patientswith Philadelphia chromosome-positive or Philadelphia
chromosome-likeALL patientswith ABL class fusion transcripts (Schultz
et al., 2014; Chalandon et al., 2015; Roberts et al., 2014). Recent techno-
logic advances have enabled detailed characterization of the genomic
landscape of childhood ALL, including DNA sequence abnormalities
such as single nucleotide variations (SNV), small insertions or deletions
(indels) and copy number variations (CNV) (Mullighan et al., 2007);
gene expression anomalies (Roberts et al., 2014; Den Boer et al.,
2009); gene fusions due to cryptic chromosomal rearrangements
(Roberts et al., 2014; Gocho et al., 2015); and aberrant epigenetic mod-
iﬁcations including abnormal DNA methylation, histone modiﬁcations
and mutations of epigenetic modiﬁer genes (Gabriel et al., 2015). The
precise contribution of these genetic or epigenetic abnormalities to leu-
kemogenesis, the development of drug resistance and leukemic clone
evolution remains to be deﬁned (Ma et al., 2015).
Remarkable progress has been made in the treatment of ALL. Cur-
rently, the ﬁve-year overall survival rates exceed 85% in pediatric pa-
tients in developed countries (Pui et al., 2015), but remain less than
45% in adults (Jabbour et al., 2015; Bassan and Hoelzer, 2011).The
poor outcome in adults has been attributed in part to a high frequency
of unfavorable genetic subtypes of ALL, pre-existing co-morbidities,
and poor tolerance of intensive treatment.
In our previous report on large B-ALL cohorts in China, the outcome
of both adult and pediatric patients seemed less favorable than that of
the best centers in Western countries (Mi et al., 2012). The higher fre-
quency of unfavorable prognostic factors such as BCR-ABL1 and the
lower frequency of favorable factors such as ETV6-RUNX1 and
hyperdiploidy in Chinese pediatric ALL could contribute to this differ-
ence (Chen et al., 2012). However, within the same genetic subtypes
of ALL, the leukemic cells of adult patients are more resistant to treat-
ment than those of pediatric patients. For example, cures can be
achieved with intensive chemotherapy and an ABL tyrosine kinase in-
hibitor in up to 70% of children with Philadelphia chromosome-positive
ALL with BCR-ABL1 fusion (Chalandon et al., 2015), but in less than 50%
of adults even with the addition of transplantation (Chalandon et al.,Fig. 1. Flow chart of B-ALL patients in this study. A total of 383 patients including 179 adults (N
study. The 92 adults and 111 children with sufﬁcient samples for next-generation sequencin
recurrent cohort, were screened for recurrent gene mutations and fusion genes.2015; Jabbour et al., 2015). In a recent study ofMLL-rearranged B-ALL,
older children had more somatic mutations and had a higher frequency
of mutated epigenetic regulators than did infants (Andersson et al.,
2015), suggesting important differences in the development and prog-
nosis of leukemia between infants and older children. Thus, we under-
took a detailed analysis of B-ALL leukemic cell genomics in adults and
children to identify genetic abnormalities in a systematic way and to
discover alterations that might explain the inferior prognosis of adult
B-ALL and to identify potential therapeutic targets for this high-risk
cancer.
2. Methods
2.1. Patients and Samples
All of the B-ALL patients enrolled in this study were diagnosed and/
or treated in the Shanghai Institute of Hematology (SIH)-based hospital
network or Multicenter Hematology-Oncology Protocols Evaluation
System (M-HOPES) in China. A total of 383 patients including179 adults
(N18 years) and 204 children (≤18 years) with newly diagnosed B-cell
ALL and tissue samples available for genomic analyses were enrolled
in this study.
The 92 adults and 111 children with sufﬁcient bone marrow and
matched remission samples or saliva samples for one ormore of the fol-
lowing analyses formed the discovery cohort:whole-exome sequencing
(201 patients), whole-genome sequencing (9), whole-transcriptome
sequencing (172) and copy number alteration analysis (202) (Fig. 1).
The features for these patients are reported in Table 1 (Table S1 for indi-
vidual patients) and are in concordance with the data we previously re-
ported (Mi et al., 2012; Chen et al., 2012).
Targeted deep sequencing for genemutations and reverse transcrip-
tase (RT)-PCR for recurrent fusion genes were performed in an addi-
tional 87 adults and 93 children, designated the recurrent cohort.
Adult patients in discovery cohortweremostly enrolled in an SIH proto-
col [Chinese Clinical Trial Registry, number ChiCTR-RNC-14004969 (for
sample collection) and ChiCTR-ONRC-14004968 (for treatment)]which
were basically a modiﬁed VDLCP regimen. Pediatric patients in discov-
ery cohort were mostly enrolled in the Shanghai Children's Medical
Center ALL-2005 protocol (Chinese Clinical Trial Registry, number
ChiCTR-ONC-14005003). Other patients in the recurrent cohort were
treated as described in detail previously (Mi et al., 2012). Fifteen pa-
tients 17 to 18 years old were treated with the adult clinical trial. The18 years) and 204 children (≤18 years) with newly diagnosed B-ALL were enrolled in this
g formed the discovery cohort. An additional 87 adults and 93 children, designated the
Table 1
Clinical characteristics and genetic types of patient cohorts.
Discovery cohort Recurrent cohort
Adult Pediatric Adult Pediatric
Number 92 111 87 93
Age at diagnosis (year)
Median 31.4 5.1 36.7 6.8
Range 18.1–68.9 0.4–18.0 18.1–63.4 1.2–17.8
Gender, no. (%)
Male 48(52.2%) 63(56.8%) 43(49.4%) 63(67.7%)
Female 44(47.8%) 48(43.2%) 44(50.6%) 30(32.3%)
WBC count at diagnosis (×109/L)
Median 22.5 10.8 18.3 15.2
Range 0.4–438.6 0.9–508.8 1.1–420.0 1.1–767.7
Speciﬁc genetic abnormalities, no. (%)
BCR-ABL1 24(26.1%) 10(9.0%) 25(28.7%) 14(15.1%)
BCR-ABL1-likea 8(10.3%) 5(5.3%) – –
MLL rearranged 7(7.6%) 4(3.6%) 5(5.7%) 2(2.2%)
TCF3-PBX1 9(9.8%) 8(7.2%) 0(0.0%) 4(4.3%)
ETV6-RUNX1 0(0.0%) 22(19.8%) 1(1.1%) 13(14.0%)
ZNF384 fusionsb 9(10.0%) 6(5.7%) 4(4.6%) 2(2.2%)
MEF2D fusionsb 3(3.3%) 4(3.8%) 9(10.3%) 2(2.2%)
hyperdiploidyN50 0(0.0%) 3(2.7%) 1(1.1%) 11(11.8%)
hypodiploidy 6(6.5%) 1(0.9%) 6(6.9%) 3(3.2%)
others 26(28.3%) 48(43.2%) 36(41.4%) 42(45.2%)
a The BCR-ABL1-like signature was identiﬁed with gene expression data, which was available in 78 adults and 94 children subject to RNA-seq.
b The data ofMEF2D and ZNF384 fusions were available in 90 adults and 106 children in the discovery cohort, and 87 adults and 93 children in the recurrent cohort.
175Y.-F. Liu et al. / EBioMedicine 8 (2016) 173–183study was approved by the institution review board of each participat-
ing center. All patients, parents or guardians provided informed consent
for sample collection and research in accord with the Declaration of
Helsinki.
Bone marrow (BM) aspiration was conducted at diagnosis and
mononuclear cells were enriched by density gradient centrifugation
with Ficoll solution. Genomic DNA and total RNA were extracted using
AllPrep DNA/RNA/Protein Mini Kit (Qiagen) or TRIzol reagent
(Invitrogen). The germline control DNA was obtained from matching
peripheral blood during complete remission after standard chemother-
apy and prepared by QuickGene DNA whole blood Kit L (FUJIFILM, Life
Science), or from saliva samples collected using Oragene kits according
to the manufacturer's instructions (DNA Genotek Inc.). Morphological,
immunophenotypic and cytogenetic analyses were performed at the
time of diagnosis. The transcripts of BCR-ABL1, ETV6-RUNX1, TCF3-
PBX1, MLL-MLLT1 and MLL-AFF1 fusion genes, as well as the transcrip-
tional expression of CRLF2 and IKZF1 were detected as previously de-
scribed (Chen et al., 2012).2.2. Genomic Analysis and Functional Experiments
The details of next-generation sequencing, gene expression and sin-
gle-nucleotide-polymorphism microarray proﬁling and functional ex-
periments are provided in Supplementary methods.2.3. Statistical Analysis
Comparisons of categorical variables were determined by Pearson's
Chi-square test or Fisher's exact test. Survival was measured from the
date of diagnosis of B-ALL to the date of death from any cause or to
the date of last contact. The database frozen on December 3, 2015 was
used for analysis. The Kaplan-Meier method was used to calculate esti-
mates of survival probabilities, which were compared by the log-rank
test. TheWelch's t-test was used for the luciferase reporter assay, chro-
matin immunoprecipitation (ChIP) assay, ﬂow cytometry assay and
comparisons of mutation numbers in adults and children. Two-sided P
values less than 0.05 were considered statistically signiﬁcant. Analyses
were performed with the use of SPSS 22.0 software and R3.2.2.2.4. Acknowledgements and Role of the Funding Source
We are indebted to colleagues from SIH and Department of Hema-
tology, Rui Jin Hospital. We are grateful to all the patients who partici-
pated in the study. We also thank Drs. Wei-Wu He and Ke-Hu Yuan
(OriGene Technologies) for kindly providing the plasmids of wild-type
full-length ZNF384, MEF2D, HNRNPUL1, BCL9, EP300 and HDAC9 cDNAs
constructed into the CMV6 vector. This work was supported by Chinese
National Key Basic Research Project 973 grant (2013CB966800), Nation-
al High Tech Program for Biotechnology grant 863 (2012AA02A505),
Ministry of Health grant (201202003), Mega-projects of Scientiﬁc Re-
search for the 12th Five-Year Plan Grant (2013ZX09303302), National
Natural Science Foundation of China grants (81123005, 81200373,
81570122), the Samuel Waxman Cancer Research Foundation Co-Prin-
cipal Investigator Program, The Program for Professor of Special Ap-
pointment (Eastern Scholar) at Shanghai Institutions of Higher
Learning (QD2015005) and the Program of Shanghai Subject Chief Sci-
entist (16XD1402000). These funding sources played key supportive
role for data and sample collection, experiments of genomic proﬁling
and molecular analysis of patient samples, in vitro and in vivo studies
of gene functions, bioinformatics and data analysis, aswell as data inter-
pretation. This work was also supported by Grants No. CA21765,
U01GM92666, and P50 GM115279 from the National Institutes of
Health, Cancer Center support grant P30 CA021765 from theUSNation-
al Cancer Institute, and the American Lebanese Syrian Associated Char-
ities, in data analyses and interpretation.3. Results
3.1. Overview of Sequence Mutations, Copy Number Alterations and Gene
Fusions
We addressed the frequencies of single nucleotide transitions and
transversions of the coding regions and entire genomic regions in the
whole-exome sequencing and whole-genome sequencing datasets, re-
spectively. It was noted that in both sequencing analyses, themost com-
monmutation types were transitions including C/G to T/A and A/T to G/
C (Fig. 2a). In total, 2336 non-silent mutations within 1779 genes were
conﬁrmed in the primary leukemia samples of 203 cases (Table S2). A
176 Y.-F. Liu et al. / EBioMedicine 8 (2016) 173–183tendency of the mutation load increasing with the age was observed
(P b 0.001, Fig. 2b). These mutations consisted predominantly of mis-
sense ones (n = 1954; 83.6%), followed by nonsense mutations (n =
132; 5.7%), frameshift due to small indels (n = 128; 5.5%), in‐frame
indels (n = 66; 2.8%) and splice‐site variants (n = 56; 2.4%) (Fig. 2c).
Across 203 sequenced samples, the number of non-silent coding
mutations (Table S2) in each individual varied signiﬁcantly (range, 0–
88), with a median of 11 mutations (range, 3–88) per adult case and 9
mutations (range, 0–45) per pediatric case (P=0.004, Fig. 3a). In addi-
tion to the well-established genes involved in B-ALL pathogenesis such
as PAX5 and RAS family members, to identify possible “driver” muta-
tions related to leukemogenesis, we mainly focused on the recurrent
ones. We also used PolyPhen2, SIFT and PROVEAN tools to predict the
possible effect of amino acid changes on the normal functions of the
proteins (Adzhubei et al., 2010; Choi and Chan, 2015). Indeed, 76.4%
(1481/1938) of the missense mutations available for either of these
tools was predicted to be deleterious (Table S2). Three hundred and
twenty-ﬁve genes were recurrently mutated, 105 (32.3%) of which
were not described before in B-ALL (Table S3). Themost frequentlymu-
tated genes are listed in Fig. 3b, after exclusion of very large size genes
with lower selection pressure (Greenman et al., 2007). Notably, muta-
tions affecting ZFHX4, a member of the DNA-damage-repair pathway
that may interact with CHD4 to modulate TP53 (Chudnovsky et al.,
2014), were not previously reported in leukemia.Fig. 2. Patterns of somatic non-silentmutations identiﬁed by whole-exome sequencing (WES) a
and transversions of all non-silent SNVs in WES and WGS. (b) Correlation of mutation burden
signiﬁcant level, and a ﬁtting curve was drawn to indicate the trend. (c) Proportions of non-silSingle nucleotide polymorphism array proﬁling identiﬁed genes
with somatic copy number gains or losses that were recurrent across
91 adult patients and 111 pediatric patients analyzed (Table S4). Copy
losses of CDKN2A/2B (9p21), PAX5 (9p13) and ETV6 (12p13)were prev-
alent in both adults and children, while copy gains of RUNX1 (21q22.3)
were more enriched in children and deletions of IKZF1 (7p12.2) were
more common in adults (Fig. 4).
Besides commonly observed fusions (BCR-ABL1, E2A-PBX1, ETV6-
RUNX1,MLL-rearranged), RNA-seq of 78 adults and 94 children identi-
ﬁed 41 fusions which were not reported previously, including 29 in-
frame fusions and 12 out-of-frame fusions (Fig. 3c, Table S5 and Table
S6). Two classes of in-frame fusions – one withMEF2D as the N-termi-
nus partner and the other with ZNF384 as the C-terminus partner –
were noteworthy for their frequent occurrence in our cohort and the
disruption of partner genes involved in transcriptional regulation. An-
other class of fusion transcript with DUX4 and IGH rearrangements
was also identiﬁed.3.2. Characterization of MEF2D and ZNF384 Related Gene Fusions
From the combined data of the discovery and recurrent cohorts,
MEF2D fusions were found in 12 of 177 (6.8%) adult and 7 of 199
(3.5%) pediatric patients, with ZNF384 fusions identiﬁed in 13 of 177ndwhole-genome sequencing (WGS) in B-ALL. (a) The percentages of distinct transitions
s and the age of B-ALL patients. A linear regression model was applied to calculate R2 and
ent mutation types according to their effects on protein coding.
Fig. 3. Comparison of non-silent mutations identiﬁed bywhole-exome andwhole-genome sequencing, and gene fusions identiﬁed by RNA-seq between adult and childhood samples. (a)
Box plot of the numbers of non-silent mutations detected by whole-exome and whole-genome sequencing. (b) The distribution of the most frequently mutated genes. (c) All of the in-
frame fusions identiﬁed by RNA-seq. The fusion events underlined represent novel fusion genes. The numbers in the bars are the exact numbers of cases with each fusion. For more
commonly identiﬁed fusion genes, frequencies are indicated in the parenthesis after the numbers.
177Y.-F. Liu et al. / EBioMedicine 8 (2016) 173–183(7.3%) adult and 8 of 199 (4.0%) pediatric patients. Pediatric patients
with MEF2D fusions tended to be older (median 12.1 years old, P =
0.08). The leukemic cells with MEF2D fusions mostly had a pre-B
immunophenotype (Table S7). Among patients with available data,
the 7 children withMEF2D fusions had a signiﬁcantly worse ﬁve-year
survival than did the remaining 186 without this feature (33.3% vs.
71.2%, P = 0.01); a similar tendency was observed in adult B-ALL
(15.6% [n = 12] vs. 31.3% [n = 157], P= 0.08) (Table S8).
Leukemic cells from patients with ZNF384 fusions were more likely
to be CD10-negative than were those from other patients in both the
adult (15.8% vs. 5.3%, P = 0.04) and pediatric (18.8% vs. 2.9%, P =
0.02) cohorts; and to co-express myeloid-associated antigen CD13
and/or CD33 (13.1% vs. 0, P= 0.001 in adults; 12.1% vs. 1.7%, P= 0.02
in children) (Table S7). There were no signiﬁcant survival differences
between patients with or without ZNF384 fusions in either the adult
(38.6% [n = 12] vs. 29.6% [n = 157]) or pediatric cohort (75.0% [n =
8] vs. 69.4% [n = 185]) (Table S8). Our observation on the clinical im-
pact of the above two fusions (Fig. 5)was in concordancewith a very re-
cent report (Yasuda et al., 2016).
We identiﬁed 3 new fusion partners of MEF2D, including BCL9 (8
cases), HNRNPUL1 (8) and SS18 (2), and a single case with the known
fusion partnerDAZAP1 (Prima et al., 2005), some ofwhich could express
different fusion transcripts with distinct exon usage (Table S7).We alsoidentiﬁedﬁve partners for ZNF384 fusions: EP300 (14 cases), EWSR1 (2),
TCF3 (2) and TAF15 (2) and CREBBP (1) (Table S7). CREBBP, a histone
acetyltransferase, represented a fusion partner of ZNF384 newly identi-
ﬁed in this study (Fig. 6a), while its homolog, EP300, was described re-
cently (Gocho et al., 2015). The protein domain compositions of
MEF2D and ZNF384 gene fusions are depicted in Fig. 6a and Fig. S1,
while the nuclear localizations of MEF2D-HNRNPUL1, MEF2D-BCL9
and EP300-ZNF384 proteins were conﬁrmed (Fig. S2).
When co-cultured with SCF, interleukin 7 and Flt-3 ligand (Flt3L) to
evaluate the effects of MEF2D fusions on hematopoietic development
(Hirose et al., 2002), MEF2D-HNRNPUL1 and MEF2D-BCL9 signiﬁcantly
inhibited the differentiation of mouse Lin− c-KitLow cells into CD19+ B-
cells in vitro (Fig. S3a). In parallel, in a retrovirus-mediated BM trans-
plantation model, ectopic expression of MEF2D fusions resulted in a
striking increase in the proportion of early immature B-cells (B220+,
CD43+) and decrease in B220+, CD19+ subset in BM (Opferman et al.,
2003) (Fig. 6b)with a concomitant decrease of B220+ cells in peripheral
blood (Fig. 6c). These results suggested an impairment of B-cell devel-
opment. Compared to wild-typeMEF2D, fusion proteins showed mark-
edly higher transactivating activities forHDAC9, a known transcriptional
target of MEF2D (Haberland et al., 2007) (Fig. 6d). Both chimeric pro-
teins directly interacted with the HDAC9 promoter region as evidenced
by ChIP, and this interaction was much stronger for fusion proteins
Fig. 4. Spectrum of acquired CNVs between adult (a) and childhood (b) samples. Copy number gain and loss were indicated red or green separately.
Fig. 5.Overall survival of adult andpediatric B-ALLwith the fusions involvingMEF2D and ZNF384 genes. (a) Kaplan-Meier survival curves of adult B-ALL patients. (b) Kaplan-Meier survival
curves of pediatric B-ALL patients.
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combination, was regulated by HDAC9, which was veriﬁed in JM-1, a
pre-B leukemia cell line (Fig. 6f). In fact, B-ALL blasts harboringMEF2D
fusions showed extremely high levels of HDAC9 transcripts and down-
regulation of RAG1 (Fig. S3b). Similarly, EP300-ZNF384 completely
blocked the differentiation of mouse Lin− c-KitLow cells into CD19+ B-
cells in vitro (Fig. S4a), and mice transplanted with EP300-ZNF384-ex-
pressing BM cells were largely void of B-cells in peripheral blood (Fig.
6g). Notably, EP300-ZNF384mice developed acute leukemia with a me-
dian survival of 100 days (Fig. 6h), with characteristic leukocytosis, ane-
mia, splenomegaly (Fig. S4b, Fig. S4c) and an accumulation of blast cells
in BM (Fig. 6i). The leukemic blasts were monoblastic in appearance
with a signiﬁcant inhibition of naphthol AS-D acetate esterase activities
by sodium ﬂuoride (Fig. 6j). Flow cytometry analysis further conﬁrmed
a striking expansion of c-Kit+ blasts with a severe reduction of lym-
phoid compartments (Fig. 6k). According to a recent redeﬁnition of
the hematopoietic hierarchy, hematopoiesis does not follow a rigid
model of myeloid-lymphoid segregation and the myelomonocytic line-
age is tied to lymphoid fate (Notta et al., 2016). Secondary transplanta-
tion of the EP300-ZNF384 mouse leukemic blasts led to even more
pronounced disease progression (Fig. 6h).
3.3. Gene Expression Proﬁles and Associations with Genetic Abnormalities
Unsupervised clustering of gene expression derived from RNA-seq
of 78 adult and 94 pediatric B-ALL patients (Table S9) identiﬁed 8 dis-
tinct subgroups G1-G8 (Fig. 7) showing strong associations with onco-
genic gene fusion, karyotype abnormality or intra-genic deletion.
Leukemia with MEF2D or ZNF384 gene fusions were clustered in G1
and G5, respectively, providing strong evidence that these gene fusions
are oncogenic drivers of two distinct leukemia subtypes. The associated
expression signatures of these two subgroups were described below.
The G1 subgroup withMEF2D fusions was the closest to G2 subgroup
with TCF3-PBX1, as both showed upregulation of genes encoding pre-B-
cell receptor signaling (pre-BCR) molecules (IGHM, IGLL1 and ZAP70)
(Geng et al., 2015) and transcription factors promoting B-cell differentia-
tion (IRF4, PAX5, EBF1,BCL6 and IKZF3), togetherwith the downregulation
of CD34 and STAT5 pathway related genes (ITGA6, CCND2 and SOCS2).
However, G1was separated fromG2 by upregulated expression in sever-
al outlier genes, such asHDAC9 (Haberland et al., 2008), one of the down-
stream target genes ofMEF2D, and PTPRZ1 that shape the B-cell repertoire
(Cohen et al., 2012). The G5 subgroup driven by ZNF384 fusions exhibited
high expression of transcription factors such as GATA3 (Heavey et al.,
2003), CEBPA and CEBPB (Xie et al., 2004), all of which play key roles in
the reprogramming of B-cells into myeloid cells (Fig. S5a). This is consis-
tent with our observation of CD13/CD33 expression on primary B-ALL
blasts with ZNF384 fusions (Table S7). Strikingly, G5 had few mutations
or deletions of genes involved in B-cell development (e.g. IKZF1, PAX5,
RUNX1, ETV6) or the cell cycle (e.g. CDKN2A/2B). The JAK-STAT signaling
pathway was upregulated in leukemic cells with ZNF384 fusions, in con-
trast to its downregulation in leukemic cells withMEF2D fusions, which
may rely on pre-BCR signaling for survival (Fig. S5b).
In other subgroups includingG3, G4, G6, G7 andG8, the dominant ge-
netic subtypes were ETV6-RUNX1, ERG deletion, hyperdiploidy, MLL-
rearranged, BCR-ABL1 or BCR-ABL1-like, respectively. The characteristic
expression proﬁles were summarized in Supplementary Results. Of
note, all cases of G4 subgroup (dominated by ERG deletion) were found
to exhibit over-expression ofDUX4 genemostly due to theDUX4-IGH fu-
sion as described by a very recentwork (Yasuda et al., 2016),suggesting a
possible cooperative relationship between the two events.
3.4. Comparison of Mutation Frequencies Between Adult and Pediatric
Cases
To explore the possible genetic differences between adults and chil-
dren, we ﬁrst compared the total number of non-silentmutations in thediscovery cohort and found that it was signiﬁcantly higher in adults
than in children (Fig. 3a), a ﬁnding that was also consistent across
gene expression cluster subgroups, especially G4, G7 and G8 (Fig. S6).
The combined analysis of the ﬁndings of SNV or indels from the discov-
ery and the recurrent cohorts (Table S10) revealed an interesting trend
of higher frequencies of IKZF1 (P= 0.03),MLL2 (P= 0.03), JAK3 (P=
0.047) mutations in adults, and PTPN11 (P = 0.03) mutations in chil-
dren (Table S11). Hyperdiploidy was found in 6 of our 14 pediatric pa-
tients with PTPN11 mutations but in only 36 of the other 204 without
such mutations (P= 0.03). Of our 4 adult patients with PTPN11muta-
tions, 3 had pseudodiploidy and one hypodiploidy. Moreover, epigenet-
ic modiﬁers involved in histone or DNAmethylation and demethylation
(MLL2, SETD2, ASXL1, EZH2, TET2 and KDM5C) weremutatedmore often
in adults than in children (22.9% vs. 12.7%, P= 0.009, Table S11).
3.5. Comparisons of Clinical Relevance and Cooperating Mutations in Dif-
ferent Gene Expression Subgroups
We then compared the clinical relevance of the gene expression sub-
groups in the combined group. Patients in the recurrent cohort were
assigned to each of the eight gene expression subgroups according to
the dominant genetic subtypes. Overall, adult group had a worse ﬁve-
year survival estimate than childhood one (Table S12, Table S13).
With regard to gene expression cluster subgroups, G3 (ETV6-RUNX1)
and G6 (hyperdiploid) were seen mostly in children and with quite fa-
vorable prognosis. In each of the remaining subgroups, adult cases
tended to have inferior outcome to pediatric counterparts. We then ex-
amined, in subgroups G1, G2, G4, G5, G7 and G8, the proportions of
adult versus pediatric patients with gene alterations combining the
data of SNV or indels and CNVs in each of the six signiﬁcantly mutated
pathways – B-cell development, cell cycle, epigenetic modiﬁers, RAS
signaling, JAK signaling and other signaling. The genes involved in the
pathway analysis were listed in Table S14. We found that pediatric pa-
tients (n= 10) in G5 (ZNF384 fusion) lacked alterations of B-cell devel-
opment genes as compared to adult patients (42.9%, n = 14, P=0.02).
Adult patients in G8 (BCR-ABL1 or BCR-ABL1-like) had signiﬁcantly
higher rates of somatic alterations in B-cell development genes (78.6%,
n = 56) than did pediatric patients (53.6%, n = 28, P = 0.02), but
lower frequencies of alterations affecting signaling genes other than
those in the RAS or JAK pathway (5.4% vs. 21.4%, P=0.05). For patients
in G7 (MLL-rearranged), adults had more mutations in epigenetic mod-
iﬁers compared to pediatric cases (42.9% of 28 vs. 11.8% of 17, P =
0.046). In this regard, adults hadmore frequent alterations in epigenetic
modiﬁers in all subgroups except G1 (Fig. 8a, Fig. S7). When all patients
were combined, genes involved in B-cell development and epigenetics
were mutated more frequently in adults than in children (P = 0.01
and 0.03, respectively, Fig. 8b).
4. Discussion
In this comprehensive study on the genetic landscape of B-ALL, we
found 105 genes with recurrent sequence mutations and identiﬁed 41
gene fusions including 29 in-frame ones which had not been reported
previously. Particularly, RNA-seq analysis allowed us to identify 8 gene
expression subgroups which demonstrated strong correlation with
major gene fusions or genomic copy number abnormalities. These sub-
groups also showed certain relationship to the immunophenotypes.
Of note,MEF2D and ZNF384 fusions were highly recurrent affecting
6.7% and 7.3% of adults, 3.4% and 3.9% of pediatric patients, respectively.
Leukemia cases with these two fusions comprised distinct gene expres-
sion subgroups (G1 and G5), suggesting that the fusions are oncogenic
drivers. Indeed, functional studies conﬁrmed that MEF2D-BCL9,
MEF2D-HNRNPUL1 and EP300-ZNF384 fusion genes profoundly
disrupted B-cell development in vivo and in vitro. Interestingly, MEF2D
fusions up-regulated HDAC9, a class II histone deacetylase, which in
turn could cooperate with the fusion transcription factors in the
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over, EP300-ZNF384 fusion alone rapidly gave rise to overt acute leuke-
mia. In our series, EP300-ZNF384 fusion conferred an intermediate
prognosis and the gene set enrichment analysis showed signiﬁcant up-
regulation of JAK-STAT pathway, suggestive of a potential beneﬁt from
treatment with inhibitors of this pathway. By contrast,MEF2D fusions
appeared to be associatedwith a poor prognosis in both adults and chil-
dren. It may be worthwhile to test histone deacetylase inhibitors in pa-
tients with this genotype. Moreover, we discovered a close associationbetween ERGdeletion andDUX4overexpression inG4 subgroup, and fu-
ture therapies may beneﬁt from a deeper understanding of this cooper-
ative mechanism of the two genetic defects.
While analyzing recurrent sequence abnormalities in adult and pe-
diatric B-ALL groups, we found that adult patients hadmore genemuta-
tions, especially IKZF1,MLL2, and JAK3, but fewer alterations of PTPN11
than did pediatric patients. A number of sequence mutations could co-
operate with gene fusions or aberrant expression patterns in disease
mechanisms and could exert effect on distinct clinical outcomes
Fig. 7.Unsupervised hierarchical clustering identiﬁed speciﬁc subgroups of patients with shared gene expression patterns. Columns indicate ALL patients and rows are genes. The bottom
panels show immunophenotype and genotype for each sample as well as signiﬁcantly altered genes (Fisher's exact P b 0.05) within each of the eight unique gene expression subgroups.
The immunophenotypes were determined according to the recommendation of European Group for the Immunological Characterization of Leukemias (EGIL).
Fig. 6. Schema of thewild-type and fusion proteins involvingMEF2Dand ZNF384 and results of functional studies. (a) Structural and functional domains ofwild-type proteins and themost
frequently identiﬁed fusion proteins. Arrows indicate breakpoints of thewild-type proteins. * labeled beside ZNF384 indicated two fusion points upstream of the coding region of ZNF384
(5 bp or 65 bp). (b) Representative ﬂow cytometry results of the B-cell population of GFP+ bonemarrow (BM) cells in vector control (Vector),MEF2D-HNRNPUL1 (MH) andMEF2D-BCL9
(MB) mice. The upper panel showed different B-cell subsets in total GFP+ cells (B220 vs. CD43), and bottom panel showed subsets in B220+ B-cell fraction (CD19 vs. CD43). (c) The
percentages of B220, CD3 and Mac-1 in GFP+ peripheral blood (PB) cells in Vector, MEF2D, MH and MB mice. * and ** denote differences between MH and MB with Vector. (d)
Responsiveness of the HDAC9 promoter to wild-type MEF2D and MEF2D fusions. 293T cells were cotransfected with a pGL4.15-Luc reporter containing the promoter region of HDAC9
and wild-type MEF2D or MEF2D fusions. Compared to wild-type MEF2D, MEF2D fusions displayed stronger transcriptional activity (MH vs. MEF2D, P b 0.001; MB vs. MEF2D, P =
0.03). (e) ChIP assays revealed MEF2D fusions had enhanced binding activity of HDAC9 promoter in 293T cells (MH vs. MEF2D, P = 0.01; MB vs. MEF2D, P = 0.02). ChIP DNA,
immunoprecipitated with an anti-Myc tag antibody or goat IgG, was quantiﬁed with primers ﬂanking HDAC9 promoter. (f) Cotransfection of wild-type MEF2D or MEF2D fusions
plasmids and HDAC9 shRNA in JM1. Transfection of MEF2D fusions led to the upregulation of HDAC9 and the downregulation of RAG1, by contrast, reduced expression of HDAC9mRNA
level with transient transfection of HDAC9 shRNA caused remarkable rebound of RAG1 expression. (g) Flow cytometry analysis of different lineage markers of GFP+ PB in Vector,
ZNF384, EP300-ZNF384 (EZ) four weeks after transplantation. (h) Kaplan-Meier survival curves of EZ mice (1st transplantation, n = 8; 2nd transplantation, n = 6). (i) Wright's
staining of BM cytospin samples from control and EZ mice. (j) Naphthol AS-D acetate esterase (NAS-DAE) staining (up) and inhibition of NAS-DAE staining by sodium ﬂuoride (NaF)
(bottom) of the BM of EZ mice. (k) Flow cytometry analysis of the BM of EZ mice versus vector control. *P b 0.05; **P b 0.01; ***P b 0.001.
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Fig. 8.Comparisons between adult and pediatric B-ALL patientswith regard to gene pathways. (a) Comparisonswithin each cluster subgroup excluding G3 andG6. A: number of adults; P:
number of children. (b) Comparison of all the patients.
182 Y.-F. Liu et al. / EBioMedicine 8 (2016) 173–183between different age groups. For example, the strong association of
IKZF1 alteration with Philadelphia chromosome-positive and Philadel-
phia chromosome-like B-ALL and PTPN11mutation with hyperdiploid
B-ALL suggests that the enrichment for IKZF1 in adults, and PTPN11 in
children, is associated with biases in leukemia subtype distribution be-
tween the two age groups. On the other hand, our ﬁndings of moremu-
tations within each gene expression cluster subgroup, and the
enrichment of genetic alterations affecting B-cell development and epi-
genetic modiﬁer genes in adult B-ALL as compared to pediatric patients
in several subgroups, suggest increased complexity of pathway involve-
ments and different target cells for malignant transformation with in-
creasing age, which may partly, albeit not fully, explain the dismal
prognosis in adults with B-ALL. Recent studies of clonal evolution of pe-
diatric (Ma et al., 2015; Mullighan et al., 2011) and adult (Xiao et al.,
2016) ALL found enrichment of mutations in epigenetic regulators
from diagnosis to relapse. It is thus possible that profound chromatin
changes owing to more frequent epigenetic modiﬁer abnormalities in
adult B-ALL cells confer greater drug-resistance.
We would stress that even though the total number of patients in
our study is relatively large, the number in each subgroup varies,
compromising our ability to generate statistically signiﬁcant results in
some analyses. Second, patients are arbitrarily divided into adult andpediatric age groups using 18 years as the threshold, even though
young children, adolescents, young adults and older adults differ in
their responses to treatment. Further comparisons with larger sample
sizes would allow better discrimination among a broader spectrum of
age groups. Third, patients 17 to 18 yearsmostly receive adult treatment
in China. New trials based on pediatric-type protocols would be expect-
ed to further improve outcome in these patients in the near future. In
spite of the above limitations, our genomic proﬁling of adult and pediat-
ric B-ALL provides useful clues to precisemolecular classiﬁcations of this
heterogeneous disease group and to identify newmolecular vulnerabil-
ities that could be exploited in the design of more effective targeted
therapies.
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